Detalhe da pesquisa
1.
Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients.
Ann Hematol
; 98(2): 321-330, 2019 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-30446802
2.
GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?
Blood
; 124(12): 1887-93, 2014 Sep 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-25102853
3.
Bosutinib shows low cross intolerance, in chronic myeloid leukemia patients treated in fourth line. Results of the Spanish compassionate use program.
Am J Hematol
; 90(5): 429-33, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25683327
4.
Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial.
Blood
; 120(13): 2581-8, 2012 Sep 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-22889759
5.
Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance.
Blood
; 118(17): 4547-53, 2011 Oct 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-21900193
6.
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.
Lancet Oncol
; 11(10): 934-41, 2010 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-20739218